SAGE — Sage Therapeutics Share News
0.000.00%
Last trade - 00:00- $544.97m
- $121.11m
- $41.24m
U.S. STOCKS ON THE MOVE-Affirm, Calavo Growers, Shoals Technologies
U.S. STOCKS ON THE MOVE-Spotify, Affirm, Calavo Growers
U.S. STOCKS ON THE MOVE-Sage, General Motors, Viridian
Sage climbs as Huntington's drug found to be safe in mid-stage study
Sage Therapeutics says rare disease drug found to be safe in mid-stage study (updated)
Sage Therapeutics' rare disease drug meets main goal in mid-stage study
U.S. RESEARCH ROUNDUP-Autodesk, McKesson, Microstrategy
Sage Therapeutics Inc Reports Results For The Quarter Ended In March: Earnings Summary
U.S. STOCKS ON THE MOVE-MSCI, Globe Life, EQT Corp
Sage rises as partner Biogen posts strong Q1 sales of postpartum depression pill
Sage Therapeutics Inc Expected To Post A Loss Of $1.65 A Share: Earnings Preview
U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust
Sage hits record low as Parkinson's drug development halted after mid-stage study fail
U.S. STOCKS ON THE MOVE-Hasbro, Eli Lilly, Bloom Energy
Sage plummets as co to stop Parkinson's drug development after mid-stage study fail
Brief: Sage Therapeutics Announces Topline Results From Phase 2 PRECEDENT Study Of Dalzanemdor (SAGE-718)
Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study (updated)
Sage therapeutics falls as Parkinson’s Disease drug fails in mid-stage study
Sage Therapeutics' Parkinson's drug fails in mid-stage study